• LAST PRICE
    9.1500
  • TODAY'S CHANGE (%)
    Trending Down-0.1500 (-1.6129%)
  • Bid / Lots
    8.1000/ 1
  • Ask / Lots
    12.4400/ 1
  • Open / Previous Close
    9.6050 / 9.3000
  • Day Range
    Low 8.7800
    High 9.9170
  • 52 Week Range
    Low 5.9999
    High 16.1900
  • Volume
    9,333
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 9.3
TimeVolumeSRZN
09:57 ET50009.917
10:06 ET9298.78
10:09 ET1009.1842
11:09 ET1008.85
11:25 ET1008.81
11:32 ET1008.995
01:18 ET1008.9
01:56 ET1008.96
02:39 ET1008.9926
04:00 ET3429.15
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesSRZN
Surrozen Inc
30.2M
-0.5x
---
United StatesALTS
ALT5 Sigma Corp
30.2M
-0.6x
---
United StatesIBO
Impact Biomedical Inc
30.1M
-12.5x
---
United StatesCMMB
Chemomab Therapeutics Ltd
29.6M
-1.7x
---
United StatesPMN
ProMIS Neurosciences Inc
31.2M
-5.3x
---
United StatesRNXT
RenovoRx Inc
29.0M
-2.3x
---
As of 2024-11-22

Company Information

Surrozen, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. It is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. It has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.

Contact Information

Headquarters
171 Oyster Point Blvd, Suite 400SOUTH SAN FRANCISCO, CA, United States 94080
Phone
650-475-2820
Fax
302-655-5049

Executives

Non-Executive Chairman of the Board, Independent Director
David Woodhouse
President, Chief Executive Officer
Craig Parker
Chief Financial Officer, Chief Operating Officer, Company Secretary
Charles Williams
Executive Vice President - Research
Yang Li
Independent Director
Anna Berkenblit

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$30.2M
Revenue (TTM)
$10.0M
Shares Outstanding
3.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.82
EPS
$-17.05
Book Value
$18.39
P/E Ratio
-0.5x
Price/Sales (TTM)
3.0
Price/Cash Flow (TTM)
---
Operating Margin
-266.71%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.